Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria  two rare disorders. Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria  two rare disorders. You can find many such discontinuous pairs here. You can find many such discontinuous pairs here. The companys primary drug is its spinal muscular atrophy drug Spinraza which is licensed to Biogen BIIB .
Alexion ($23 billion, -3% YTER) is a served to die for anemia.
( z0 serve :ARG1 ( z1 person :name ( z2 name :op "Alexion" ) :quant ( z3 monetary-quantity :quant 23000000 :unit ( z4 dollar ) ) :quant ( z5 percentage-entity :value 3 ) ) :ARG2 ( z6 die :ARG1 z1 :ARG1-of ( z7 cause :ARG0 ( z8 anemia ) ) ) )
(z0 / serve-02
    :ARG1 (z1 / person
              :name (z2 / name
                        :op1 "Alexion")
              :quant (z3 / monetary-quantity
                         :quant 23000000
                         :unit (z4 / dollar))
              :quant (z5 / percentage-entity
                         :value 3))
    :ARG2 (z6 / die-01
              :ARG1 z1
              :ARG1-of (z7 / cause-01
                           :ARG0 (z8 / anemia))))
Alexion ( $23 billion , - 3 % YTER ) is a served to die for anemia .
z1 :name z2
z2 :op1 2
z1 :quant z3
z3 :unit z4
z3 :quant 0
z5 :value 1
z1 :quant z5
z0 :ARG1 z1
z0 :ARG2 z6
z6 :ARG1 z1
z6 :ARG1-of z7
z7 :ARG0 z8